The debate over drug price transparency has intensified, with pharmacy benefit managers (PBMs) taking a stand in response to increasing scrutiny.
This conflict highlights the complexities involved in the pricing of medications and the various stakeholders affected by these changes.
As discussions continue, the implications for consumers and the healthcare system remain significant, warranting careful observation.